Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

A potential target for experimental drugs that block PRMT5—a naturally occurring enzyme some tumors rely more on for survival ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.

Chemotherapy-induced nausea and vomiting can severely impact patients’ quality of life and treatment adherence. In a major ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...